Tempus AI (NASDAQ:TEM) Stock Price Expected to Rise, Morgan Stanley Analyst Says

Tempus AI (NASDAQ:TEM) had its price target lifted by Morgan Stanley from $50.00 to $60.00 in a research report report published on Thursday,Benzinga reports. The firm currently has an overweight rating on the stock.

Other research analysts have also issued reports about the stock. Stifel Nicolaus lowered shares of Tempus AI from a “buy” rating to a “hold” rating and increased their target price for the stock from $45.00 to $65.00 in a research note on Monday, November 11th. JPMorgan Chase & Co. downgraded Tempus AI from an “overweight” rating to a “neutral” rating and raised their target price for the company from $50.00 to $55.00 in a research note on Tuesday, February 25th. Needham & Company LLC upped their price target on Tempus AI from $56.00 to $70.00 and gave the stock a “buy” rating in a research note on Tuesday, February 25th. Bank of America raised their price objective on Tempus AI from $54.00 to $60.00 and gave the company a “neutral” rating in a research note on Monday. Finally, Guggenheim reaffirmed a “buy” rating on shares of Tempus AI in a research report on Tuesday, February 25th. Six investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, Tempus AI presently has an average rating of “Moderate Buy” and an average target price of $61.18.

Tempus AI Price Performance

Shares of TEM opened at $48.86 on Thursday. Tempus AI has a 52-week low of $22.89 and a 52-week high of $91.45. The business’s 50 day moving average price is $53.75 and its two-hundred day moving average price is $52.57. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55.

Insider Buying and Selling at Tempus AI

In related news, CEO Eric P. Lefkofsky sold 187,655 shares of Tempus AI stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $37.54, for a total transaction of $7,044,568.70. Following the sale, the chief executive officer now directly owns 9,557,283 shares in the company, valued at approximately $358,780,403.82. This trade represents a 1.93 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Ryan M. Bartolucci sold 13,770 shares of the business’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $60.00, for a total value of $826,200.00. Following the completion of the transaction, the chief accounting officer now directly owns 57,237 shares in the company, valued at approximately $3,434,220. This represents a 19.39 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 5,844,510 shares of company stock worth $321,970,407.

Institutional Investors Weigh In On Tempus AI

A number of hedge funds have recently made changes to their positions in the business. GF Fund Management CO. LTD. purchased a new stake in shares of Tempus AI during the 4th quarter worth approximately $108,000. Voloridge Investment Management LLC purchased a new position in Tempus AI in the fourth quarter valued at approximately $11,826,000. Two Sigma Advisers LP bought a new position in Tempus AI during the fourth quarter valued at $625,000. ProShare Advisors LLC purchased a new stake in Tempus AI in the fourth quarter worth $244,000. Finally, Lazard Asset Management LLC bought a new stake in shares of Tempus AI in the fourth quarter valued at $1,034,000. 24.22% of the stock is currently owned by institutional investors.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.